Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.
Goldstone, A H
McMillan, A K
Smith, A G
Prentice, H G
Morgenstern, Godfrey R
AffiliationUniversity College and Middlesex Schools of Medicine, London, England.
MetadataShow full item record
AbstractThe results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis (four patients; one fatal), intracranial hemorrhage (two patients; two fatal) has occurred. There have been four procedure-related deaths (12%). Hematologic recovery was satisfactory for neutrophils (median time to 0.5 x 10(9)/L, 22 days [range, 11 to 101 days]), but very slow for platelets (median time to 50 x 10(9)/L, 62 days [range, 15 to 1,080 days]). This study suggests that the use of Bu/Cy with ABMT for patients beyond first remission in AML compares favorably with chemotherapy, and although the procedure-related mortality is acceptable, it is associated with protracted platelet recovery.
CitationSuccessful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. 1991, 9 (10):1840-7 J. Clin. Oncol.
JournalJournal of Clinical Oncology
- A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
- Authors: Ringdén O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, Sierra J, Gorin NC
- Issue date: 1996 Jun
- Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission.
- Authors: Petersen FB, Lynch MH, Clift RA, Appelbaum FR, Sanders JE, Bensinger WI, Benyunes MC, Doney K, Fefer A, Martin P
- Issue date: 1993 Jul
- Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution.
- Authors: Sanz MA, de la Rubia J, Sanz GF, Martín G, Martínez J, Jarque I, Sempere A, Gomis F, Senent L, Soler MA
- Issue date: 1993 Sep
- Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
- Authors: Jerjis S, Roovers E, Muus P, Schaap N, de Witte T
- Issue date: 1998 Jul
- Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.
- Authors: Shaw PJ, Bergin ME, Burgess MA, Dalla Pozza L, Kellie SJ, Rowell G, Stevens MM, Webster BH, Bradstock KF
- Issue date: 1994 Oct